EMBC Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of 10% compared to Embecta Corp.'s net margin of -2301.55%. Embecta Corp.'s return on equity of -- beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Embecta Corp. has a consensus price target of $16.67, signalling upside risk potential of 37.97%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 43.31%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Embecta Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Embecta Corp..

Embecta Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Embecta Corp. has a quarterly dividend of $0.15 per share corresponding to a yield of 4.97%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta Corp. pays 37.05% of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Embecta Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta Corp. quarterly revenues are $264M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Embecta Corp.'s net income of $26.4M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Embecta Corp.'s price-to-earnings ratio is 7.42x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta Corp. is 0.66x versus 51.01x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Becton, Dickinson & Co. has a net margin of 10% compared to Embecta Corp.'s net margin of 8.37%. Embecta Corp.'s return on equity of -- beat Becton, Dickinson & Co.'s return on equity of 6.6%.

Embecta Corp. has a consensus price target of $16.67, signalling upside risk potential of 37.97%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.68%. Given that Embecta Corp. has higher upside potential than Becton, Dickinson & Co., analysts believe Embecta Corp. is more attractive than Becton, Dickinson & Co..

Embecta Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.

Embecta Corp. has a quarterly dividend of $0.15 per share corresponding to a yield of 4.97%. Becton, Dickinson & Co. offers a yield of 2.13% to investors and pays a quarterly dividend of $1.05 per share. Embecta Corp. pays 37.05% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta Corp. quarterly revenues are $264M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. Embecta Corp.'s net income of $26.4M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, Embecta Corp.'s price-to-earnings ratio is 7.42x while Becton, Dickinson & Co.'s PE ratio is 33.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta Corp. is 0.66x versus 2.59x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of 10% compared to Embecta Corp.'s net margin of -12425.36%. Embecta Corp.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Embecta Corp. has a consensus price target of $16.67, signalling upside risk potential of 37.97%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than Embecta Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Embecta Corp..

Embecta Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Embecta Corp. has a quarterly dividend of $0.15 per share corresponding to a yield of 4.97%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta Corp. pays 37.05% of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend. Embecta Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta Corp. quarterly revenues are $264M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Embecta Corp.'s net income of $26.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Embecta Corp.'s price-to-earnings ratio is 7.42x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta Corp. is 0.66x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of 10% compared to Embecta Corp.'s net margin of 13.19%. Embecta Corp.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Embecta Corp. has a consensus price target of $16.67, signalling upside risk potential of 37.97%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 521.47%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Embecta Corp., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Embecta Corp..

Embecta Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Embecta Corp. has a quarterly dividend of $0.15 per share corresponding to a yield of 4.97%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Embecta Corp. pays 37.05% of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend. Embecta Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Embecta Corp. quarterly revenues are $264M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Embecta Corp.'s net income of $26.4M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Embecta Corp.'s price-to-earnings ratio is 7.42x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Embecta Corp. is 0.66x versus 2.25x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.